Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019–2023)
The results of this investigation provide a valuable benchmark for monitoring the in vitro activity of aztreonam/avibactam after its clinical approval in Europe and emphasizes the importance of comprehensive surveillance programmes to monitor the emergence of high-risk clones and resistance mechanisms to newly approved antimicrobial agents.
Authors
- John H. Kimbrough (ORCID: https://orcid.org/0000-0002-0457-1543)
- Rodrigo E. Mendes (ORCID: https://orcid.org/0000-0002-8648-1137)
- Mariana Castanheira (ORCID: https://orcid.org/0000-0003-0126-1782)
- Marisa Winkler (ORCID: https://orcid.org/0000-0002-9785-5034)
- Hélio S. Sader (ORCID: https://orcid.org/0000-0001-7022-6644)
Institutions
- JMI Laboratories (US)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1093/jac/dkaf161
- Citations
- 9
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 5.32
Funders
- Pfizer